Clinical Events After Cessation of Lamivudine Therapy in Patients Recovered From Hepatitis B Flare With Hepatic Decompensation

Cessation of lamivudine therapy after recovery from hepatitis B flare with decompensation was safe for most patients. However, 8.2% develop decompensation within 1 year and can be rescued by timely retreatment. With close monitoring, the stopping strategy could be a feasible alternative to indefinite therapy, especially in low resource settings.